Juvenile Inflammatory Rheumatism (JIR) Cohorte

Setting up a Pediatric Cohort for Inflammatory Rheumatic Diseases

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02377245

Acronym

JIR-cohorte

Enrollment

15000

Registered

2015-03-03

Start date

2014-01-31

Completion date

2030-12-31

Last updated

2023-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Juvenile Rheumatoid

Keywords

Juvenile, Inflammatory, Rheumatism, Pediatric-Onset inflammatory diseases

Brief summary

The investigators created a cohort of patients with juvenile inflammatory rheumatisms with the purpose to follow them prospectively, and investigate the tolerance and efficacy of immunosuppresive and biological agents.

Detailed description

The JIR-cohort has to be filled by an authorized investigator during or after the consultation. Each patient much be followed at least once a year. Different data are requested in the JIR-cohort: diagnosis, treatment, adverse events and outcome.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with juvenile inflammatory diseases * Age at onset up to 18 years old * Consent according national codes of ethics and current laws

Exclusion criteria

* Non-consent from patients and/or legal representative

Design outcomes

Primary

Measure	Time frame
Number of severe and very severe adverse event as a mesure of safety and tolerability	10 years
Number of treatments prescribed off label	10 Years
Length in months of drug survival in patient treated with at least two consecutive biological agents	10 Years

Countries

Belgium, France, Germany, Morocco, Switzerland

Outcome results